{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:49:49Z","timestamp":1791838189914,"version":"4.3.4"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejca.2018.08.016","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T14:05:22Z","timestamp":1538748322000},"page":"9-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5918-4738","authenticated-orcid":false,"given":"Mariana M.","family":"Fachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-8608","authenticated-orcid":false,"given":"Fernanda S.","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0927-3120","authenticated-orcid":false,"given":"Leticia P.","family":"Leonart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina S.","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4829-1703","authenticated-orcid":false,"given":"Luana","family":"Lenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonald C.","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-9595","authenticated-orcid":false,"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-4363","authenticated-orcid":false,"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.ejca.2018.08.016_bib1","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"Hoglund","year":"2015","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.016_bib2","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA A Cancer J Clin"},{"issue":"5405","key":"10.1016\/j.ejca.2018.08.016_bib3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ejca.2018.08.016_bib4","first-page":"3025","article-title":"Tyrosine kinase inhibitors in Ph+ chronic myeloid leukemia therapy: a review","volume":"17","author":"Shah","year":"2016","journal-title":"Asian Pac J Cancer Prev: APJCP"},{"issue":"12","key":"10.1016\/j.ejca.2018.08.016_bib5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/cncr.11831","article-title":"Imatinib mesylate therapy improves survival in patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2018.08.016_bib6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2018.08.016_bib7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2018.08.016_bib8","series-title":"NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia version 2","first-page":"2017","author":"Network","year":"2018"},{"issue":"Suppl 2","key":"10.1016\/j.ejca.2018.08.016_bib9","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann Hematol"},{"issue":"17","key":"10.1016\/j.ejca.2018.08.016_bib10","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ejca.2018.08.016_bib11","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/ajh.24536","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.ejca.2018.08.016_bib12","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.08.016_bib13","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1200\/JCO.2017.35.15_suppl.7012","article-title":"Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts)","volume":"35","author":"Kantarjian","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.08.016_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bdq.2017.01.001","article-title":"Molecular techniques for the personalised management of patients with chronic myeloid leukaemia","volume":"11","author":"Alikian","year":"2017","journal-title":"Biomol Detect Quantification"},{"key":"10.1016\/j.ejca.2018.08.016_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.016_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2162-3619-2-5","article-title":"The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis","volume":"2","author":"Mealing","year":"2013","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.016_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ctrv.2013.09.004","article-title":"Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis","volume":"40","author":"Signorovitch","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.ejca.2018.08.016_bib18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.ejca.2018.08.016_bib19","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2018.08.016_bib20","series-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0","author":"Higgins","year":"2011"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.016_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.016_bib22","doi-asserted-by":"crossref","first-page":"943","DOI":"10.18549\/PharmPract.2017.01.943","article-title":"Network meta-analysis: a technique to gather evidence from direct and indirect comparisons","volume":"15","author":"Tonin","year":"2017","journal-title":"Pharm Pract (Granada)"},{"issue":"4","key":"10.1016\/j.ejca.2018.08.016_bib23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.ejca.2018.08.016_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.ejca.2018.08.016_bib25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"issue":"20","key":"10.1016\/j.ejca.2018.08.016_bib26","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.016_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"key":"10.1016\/j.ejca.2018.08.016_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"Van Valkenhoef","year":"2015","journal-title":"Res Synth Meth"},{"issue":"7\u20138","key":"10.1016\/j.ejca.2018.08.016_bib29","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.016_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ejca.2018.08.016_bib31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"Van Valkenhoef","year":"2012","journal-title":"Res Synth Meth"},{"issue":"19","key":"10.1016\/j.ejca.2018.08.016_bib32","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejca.2018.08.016_bib33","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.ejca.2018.08.016_bib34","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.08.016_bib35","first-page":"1","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","author":"Cortes","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.016_bib36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.12618","article-title":"Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia","volume":"164","author":"Deininger","year":"2014","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.ejca.2018.08.016_bib37","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2018.08.016_bib38","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ejca.2018.08.016_bib39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ejh.12423","article-title":"Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)","volume":"94","author":"Hjorth-Hansen","year":"2015","journal-title":"Eur J Haematol"},{"issue":"24","key":"10.1016\/j.ejca.2018.08.016_bib40","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejca.2018.08.016_bib41","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-17-0957","article-title":"Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia","volume":"23","author":"Kwak","year":"2017","journal-title":"Clin Canc Res"},{"issue":"5","key":"10.1016\/j.ejca.2018.08.016_bib42","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2018.08.016_bib43","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","article-title":"A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"120","author":"Radich","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ejca.2018.08.016_bib44","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2018.08.016_bib45","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","article-title":"Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2018.08.016_bib46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.critrevonc.2015.08.020","article-title":"Chronic myeloid leukemia: relevance of cytogenetic and molecular assays","volume":"97","author":"Bennour","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.016_bib47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ajh.24275","article-title":"Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.016_bib48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1309\/AJCPUN89CXERVOVH","article-title":"Chronic myelogenous leukemia, BCR-ABL1+","volume":"132","author":"Vardiman","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2018.08.016_bib49","first-page":"151","article-title":"Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia","volume":"3","author":"Bauer","year":"2012","journal-title":"J Adv Pract Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2018.08.016_bib50","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1634\/theoncologist.2010-0055","article-title":"Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy","volume":"15","author":"Press","year":"2010","journal-title":"Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.08.016_bib51","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.016_bib52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2018.08.016_bib53","series-title":"American society of clinical oncology educational book American society of clinical oncology meeting","first-page":"167","article-title":"Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor","author":"Baccarani","year":"2014"},{"key":"10.1016\/j.ejca.2018.08.016_bib54","volume":"2016","author":"Network","year":"2016"},{"issue":"8","key":"10.1016\/j.ejca.2018.08.016_bib55","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/10428194.2016.1265116","article-title":"Current trends in molecular diagnostics of chronic myeloid leukemia","volume":"58","author":"Vinhas","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.ejca.2018.08.016_bib56","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/cam4.801","article-title":"Deep molecular responses for treatment-free remission in chronic myeloid leukemia","volume":"5","author":"Dulucq","year":"2016","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.016_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ejca.2018.08.016_bib58","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ejca.2018.08.016_bib59","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMe1210796","article-title":"Ponatinib for chronic myeloid leukemia","volume":"367","author":"Goldman","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2018.08.016_bib60","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","article-title":"Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejca.2018.08.016_bib61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.ejca.2018.08.016_bib62","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'Hare","year":"2012","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.ejca.2018.08.016_bib63","first-page":"1","article-title":"BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival","author":"Pagnano","year":"2015","journal-title":"Cancer Invest"},{"issue":"11","key":"10.1016\/j.ejca.2018.08.016_bib64","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1089\/gtmb.2012.0147","article-title":"ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan","volume":"16","author":"Awidi","year":"2012","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.ejca.2018.08.016_bib65","first-page":"E1","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2018.08.016_bib66","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1470-2045(16)30064-X","article-title":"Ponatinib for chronic myeloid leukaemia: future perspectives","volume":"17","author":"Fava","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.016_bib67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","article-title":"Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"16","author":"Haguet","year":"2017","journal-title":"Expet Opin Drug Saf"},{"issue":"9","key":"10.1016\/j.ejca.2018.08.016_bib68","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/S2352-3026(15)00127-1","article-title":"Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2018.08.016_bib69","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2011.01.016","article-title":"Nilotinib: a novel, selective tyrosine kinase inhibitor","volume":"38","author":"Blay","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2018.08.016_bib70","first-page":"89","article-title":"Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib","volume":"3","author":"Swords","year":"2009","journal-title":"Drug Des Dev Ther"},{"issue":"4","key":"10.1016\/j.ejca.2018.08.016_bib71","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4103\/0019-509X.92274","article-title":"Nilotinib as first-line therapy for chronic myeloid leukemia","volume":"48","author":"Vaid","year":"2011","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.ejca.2018.08.016_bib72","first-page":"151","article-title":"First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation","volume":"3","author":"Piccaluga","year":"2012","journal-title":"Hematol Res Rev"},{"key":"10.1016\/j.ejca.2018.08.016_bib73","first-page":"23","article-title":"Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib","volume":"10","author":"Emole","year":"2016","journal-title":"Biol Targets Ther"},{"issue":"10","key":"10.1016\/j.ejca.2018.08.016_bib74","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"An","year":"2010","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.ejca.2018.08.016_bib75","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"6","key":"10.1016\/j.ejca.2018.08.016_bib76","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.clml.2016.03.003","article-title":"Comparative effectiveness of newer tyrosine kinase inhibitors versus imatinib in the first-line treatment of chronic-phase chronic myeloid leukemia across risk groups: a systematic review and meta-analysis of eight randomized trials","volume":"16","author":"Yun","year":"2016","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.016_bib77","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2009.08.031","article-title":"Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia","volume":"34","author":"Breccia","year":"2010","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.ejca.2018.08.016_bib78","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clml.2012.04.002","article-title":"Adherence to BCR-ABL inhibitors: issues for CML therapy","volume":"12","author":"Jabbour","year":"2012","journal-title":"Clinical lymphoma, myeloma & leukemia"},{"issue":"14","key":"10.1016\/j.ejca.2018.08.016_bib79","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ejca.2018.08.016_bib80","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2018.08.016_bib81","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.016_bib82","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5581\/1516-8484.20140014","article-title":"Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"36","author":"de Almeida","year":"2014","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"12","key":"10.1016\/j.ejca.2018.08.016_bib83","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1185\/03007995.2010.533648","article-title":"Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.016_bib84","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1185\/03007995.2011.649849","article-title":"Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia","volume":"28","author":"Yood","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejca.2018.08.016_bib85","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","author":"Bixby","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"issue":"7","key":"10.1016\/j.ejca.2018.08.016_bib86","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.bbapap.2012.12.009","article-title":"Mechanisms of resistance to BCR-ABL and other kinase inhibitors","volume":"1834","author":"Lamontanara","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.ejca.2018.08.016_bib87","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2040620712468289","article-title":"Management of imatinib-resistant patients with chronic myeloid leukemia","volume":"4","author":"Bhamidipati","year":"2013","journal-title":"Therapeut Adv Hematol"},{"issue":"22","key":"10.1016\/j.ejca.2018.08.016_bib88","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1200\/JCO.2008.19.4076","article-title":"Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance","volume":"27","author":"Zhang","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2018.08.016_bib89","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/leu.2015.42","article-title":"Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1","volume":"29","author":"Zabriskie","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2018.08.016_bib90","series-title":"American society of hematology annual meeting","first-page":"30","article-title":"In CML: radotinib as frontline therapy; ponatinib promising for T315I patients","author":"Fuerst","year":"2016"},{"issue":"7","key":"10.1016\/j.ejca.2018.08.016_bib91","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2013.096776","article-title":"Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors","volume":"99","author":"Kim","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.016_bib92","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.24249","article-title":"Chronic myeloid leukemia: first-line drug of choice","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.ejca.2018.08.016_bib93","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2018.08.016_bib94","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ejca.2018.08.016_bib95","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1016\/j.ejca.2018.08.016_bib96","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ejca.2018.08.016_bib97","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.08.016_bib98","first-page":"231","article-title":"Ponatinib efficacy and safety in philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejca.2018.08.016_bib99","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","article-title":"Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1\/2 study","volume":"103","author":"Gambacorti-Passerini","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ejca.2018.08.016_bib100","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JOP.2016.019737","article-title":"Journey of generic imatinib: a case study in oncology drug pricing","volume":"13","author":"Chen","year":"2017","journal-title":"J Oncol Pract"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:22:13Z","timestamp":1760732533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918313327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":100,"alternative-id":["S0959804918313327"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.08.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}